Purdue researcher awarded $1.3 million for malaria drug trials in Southeast Asia and Africa
While studying how malaria propagates in human blood, Low and his research team discovered that the cancer drug therapy imatinib is effective in the treatment of drug-resistant malaria.
- While studying how malaria propagates in human blood, Low and his research team discovered that the cancer drug therapy imatinib is effective in the treatment of drug-resistant malaria.
- Trials in Southeast Asia showed that imatinib, when combined with the customary malaria therapy, clears all malaria parasites from 90% of patients within 48 hours and 100% of patients within three days .
- Open Philanthropy has awarded Low $600,000 for a larger clinical trial in Southeast Asia to validate his previous trials.
- His work also receives support from the Purdue Institute for Cancer Research and the Purdue Institute for Drug Discovery .